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Abstract 
Background: Hypertension is as prevalent in many developing countries, as in the developed world and is the 
leading cause of cardiovascular morbidity and mortality in Africa. The control of hypertension in this resource limited 
setting is inadequate, a situation that translates into poorer outcomes in form of increasing incidences of stroke, heart 
failure, kidney failure and therefore early cardiovascular death.
Methods: This was a chart review of all the patients seen during the months of September 2012 to February 2013. 
We determined the level of blood pressure control, basic investigations documented as well as the choice of hyper-
tensive treatment among patients attending a hypertension clinic in a national referral hospital, Mulago.
Results: Of the 741 patients whose charts were reviewed the median age was 60 years, Inter quartile range (IQR) 
was 51–71. Six hundred forty-two (86.6%) were females. Blood pressure (BP) control defined as BP lowering to at least 
140/90 was seen in only 198 (26.7%) patients. Biophysical measurement documentation was very low especially for 
waist and hip circumference at 0.3%. Majority of patients, 476 (64.2%) had at least one documented investigation for 
the complications of hypertension. Only 103 (13.9%) had all investigations documented in their charts. The investiga-
tions included; complete blood count (CBC), urinalysis, renal function tests (RFTs), Chest X-Ray (CXR), echocardiogra-
phy (Echo) and electrocardiography (ECG). The commonly documented investigations were RFTs (45.5%), ECG (45.2%) 
and Echo (44.2%). The commonly prescribed anti hypertensive medications were; Angiotensin receptor blockers 
(ARBs)/Angiotensin converting enzyme inhibitors (ACEI) (72.74%), calcium channel blockers (72.3%) and thiazide diu-
retics (68.6%). Majority of patients were receiving three anti hypertensive medications 313 (42.2%), with 149 (43.6%) of 
these, on an ACEI/ARB, a calcium channel blocker and a thiazide diuretic.
Conclusion: Blood pressure control is suboptimal in a tertiary clinic setting at Mulago hospital and documenta-
tion of investigations is inadequate. ARB/ACEI, Calcium channel blockers and thiazide diuretics were the commonly 
prescribed anti hypertensive medications. There is a great need to investigate for renal and cardiac complications as 
well as exploring reasons for inadequate blood pressure control and consider appropriate interventions to avert bad 
outcomes.
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Background
Hypertension affects about one billion people and is esti-
mated to cause 4.5% of current global disease burden [1, 2]. 
There is a strong relationship between blood pressure 
control and cardiovascular mortality and morbidity [3]. 
Hypertension is the leading cause of cardiovascular mor-
bidity and mortality in Africa where it affects young and 
active adults [4, 5]. The control of hypertension in this 
resource limited setting is likely to be inadequate, a situ-
ation that translates into poorer outcomes in the form of 
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increasing incidences of stroke, heart failure, kidney fail-
ure and therefore cardiovascular death [6–8].
There is evidence that the diagnosis and control of 
hypertension is crucial in decreasing disability and mor-
tality [9]. A meta analysis done by Lewington et al. dem-
onstrated that BP reduction of 20/10 is associated with 
more than a twofold reduction in stroke death rate, and 
with twofold differences in the death rates from ischemic 
heart disease and from other vascular causes. [10].
Blood pressure elevation is usually a multifactorial con-
dition, and therefore it is almost impossible to normalize 
pressure by targeting only one mechanism. In addition, 
drug therapy directed at any one component routinely 
evokes counter regulatory responses that reduce the 
magnitude of response. Clinical trials have documented 
that achieving BP targets is usually not possible with a 
single agent. In the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial [11], only 26% of 
patients achieved goal BP with monotherapy. In contrast, 
combined therapy has been shown to improve control of 
blood pressure in an increased number of patients [12]. 
In addition to the improved efficacy of combination ther-
apy, this strategy may have fewer side effects.
Blood pressure targets and choice of drugs are dependent 
on co-morbidity or presence of any target organ damage 
and so in the routine screening for patients with hyperten-
sion it is pertinent that some tests are done [13, 14].
There has been documented poor BP control among 
community studies [15]. However there have not been 
many studies that have evaluated clinic blood pressure 
control [16]. The utility of studying clinic based control 
lies in having the opportunity to work up patients for sec-
ondary causes and plan interventions.
In an attempt to improve patient care in our hyperten-
sion clinics, we determined the level of blood pressure 
control, basic investigations documented and the choice 
of hypertensive treatment among patients attending the 




This was a chart review of all the patients seen through 
the months of September 2012 to February 2013.
The study was conducted at the hypertension clinic in 
the medical out patients’ department of Mulago National 
referral hospital. The hospital is located in Uganda’s 
capital—Kampala and doubles as the teaching hospital 
for Makerere University College of health sciences. This 
clinic runs every Monday except on public holidays. The 
clinic is run by physicians, medical doctors and nurses 
plus support from the laboratory and pharmacy. About 
80–100 patients are reviewed on a given clinic day.
Data collection
We used the records book at the hypertension clinic 
to get a list of all the patients that attended the clinic 
through the months of September 2012 to February 
2013, their files were retrieved and data was abstracted 
using a pretested tool. The team that collected data 
was trained before data was abstracted. The data 
abstraction form was piloted and adjusted to get the 
required information. The data collected included: 
socio-demographics [patient sex, and age], co-mor-
bidities including diabetes mellitus, obesity, chronic 
kidney disease, stroke and clinical characteristics 
such as blood pressure, weight, height, and waist–hip 
circumference.
The investigations included: Renal function tests 
(RFTs), electrolytes, urinalysis, echocardiography, elec-
trocardiogram (ECG) and Chest X-ray.
We also obtained information on the type of drugs pre-
scribed to the patient.
Operational definitions
An individual was classified to have sub-optimal pres-
sure control if his/her blood pressure measurement 
was  ≥140/90  mmHg on the last clinic visit. A missed 
appointment was defined as coming back to the clinic 
more than one week after a scheduled appointment.
Data analysis
Data were collected manually and captured into Epi-data 
before it was transferred to STATA version 12 for analy-
sis. Categorical variable are expressed as percentages and 
continuous data as median with their corresponding inter 
quartile range. Logistic regression was done to determine 
factors associated with blood pressure control. Statistical 
significance was set at p < 0.05.
Ethical consideration
This research project was approved by the research and 
ethics committee of Mulago national referral hospital.
Results
Of the 741 charts reviewed; 642 (86.6%) belonged to 
female subjects; the median age was 60 years Inter quar-
tile range IQR (51–71). More than two-thirds 548 (74%) 
of patients were 50 years and above.
Blood pressure less than 140/90 mmHg
Blood pressure control as defined as at least 140/90 was 
seen in only 198 (26.7%) of the patients whose charts 
were reviewed. Blood pressure control was better among 
female patients. Age was comparable among patients 
with good blood pressure control and those not con-
trolled (Table 3).
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Co‑morbidity
Ninety patients (12.2%) had documented co-morbid con-
ditions. Stroke was in 14 (1.9%), Human immunodefi-
ciency virus (HIV) infection was documented among 17 
(2.3%), diabetes 11 (1.5%), asthma 11 (1.5%), arthritis 8 
(1.1%), dyslipidemia 4 (0.5%) and benign prostatic hyper-
trophy in 4 (0.5%). Other conditions documented at very 
low frequency were renal disease, deep venous thrombo-
sis, obstructive pulmonary disease, hyperthyroidism and 
peptic ulcer disease.
Biophysical measurement
The proportion of patients with biophysical measure-
ment was very low especially for waist–hip circumference 
(Table  1). Weight was documented among 266 (34%) 
patients, height in 169 (22.5%) patients, while waist–hip 
circumference were documented among (0.3%) patients 
whose charts were reviewed.
Documented investigations
While the majority of patients had at least one docu-
mented investigation 476 (64.2%), only 103 (13.9%) had 
all the expected investigations documented in their 
charts. The expected investigations included CBC, uri-
nalysis, renal function test, chest X-ray, echocardiogram 
and electrocardiography. The commonly documented 
investigations included RFTs (45.5%), ECG (45.2%) and 
Echo (44.2%) (Table 1).
Medication
Several classes of anti hypertensive medications were 
used (Table 1). The most commonly prescribed medica-
tions were angiotensin receptor blockers (ARBs)/angio-
tensin converting enzyme inhibitors (ACEI) (72.74%), 
calcium channel blockers (72.3%), thiazide diuretics 
(68.6%) and beta blockers (52.2%). The least prescribed 
drugs were the centrally acting vasodilators and potas-
sium sparing diuretics which were prescribed among 4.9 
and 3.2% respectively. The use of a beta blocker, ACEi, 
calcium channel blocker or a thiazide was associated 
with poor blood pressure control (Table 3).
Majority of patients were receiving three anti hyperten-
sive medications 313 (42.2%), with 149 (47.6%) of these 
on an ACEI/ARB, a calcium channel blocker and a thi-
azide (Table 2).
Blood pressure control varied across number of anti-
hypertensive drugs used and was worse among patients 
taking 3 and 4 drugs; odds ratio (95% confidence interval) 
0.32 (0.16–0.62) and 0.17 (0.08–0.37) respectively com-
pared to monotherapy (Table 3).
Other medications used included cardiac aspirin 
(23.4%), lipid lowering drugs (2.8%) and furosemide 
(5.3%).
Missed appointments
Almost half of the patients 348 (47.7%) did not keep their 
appointments. There was no difference in blood pressure 
control between those that kept appointments and those 
that did not keep appointments OR 1.03 95% CI (0.74–
1.43) p = 0.858.
Discussion
Hypertension contributes to a high burden of disease and 
increased outpatient attendance for non communicable 
diseases. In Uganda specifically at the national referral 
hospital, the hypertension clinic is one of the busiest clin-
ics with 80–100 patients reviewed each clinic day. Man-
agement of hypertension is aimed at controlling blood 
pressure to avert damage to end organs and thus improve 
quality of life for individuals with hypertension. In this 
study we found blood pressure control (as defined by a 
Table 1 Patient characteristics
ARBs Angiotensin receptor blockers, ACEi Angiotensin converting enzyme 
inhibitor
Variable Female n (%) Male n (%) Total n (%)
Age categories (years)
 <40 36 (5.8) 5 (5.2) 41 (5.7)
 40–49 111 (17.9) 15 (15.6) 126 (17.6)
 50–59 172 (27.8) 20 (20.8) 192 (26.9)
 60–69 141 (22.8) 18 (18.7) 159 (22.2)
 70–79 121 (19.6) 25 (26.0) 146 (20.4)
 80 and above 38 (6.1) 13 (13.5) 51 (7.1)
Biophysical measurements done
 Weight 234 (36.5) 30 (30.3) 264 (35.6)
 Height 148 (22.7) 20 (20.2) 168 (22.7)
 WHR 2 (0.3) 0 2 (0.3)
Investigations done
 Complete blood count 231 (36.0) 35 (35.4) 266 (35.9)
 Urinalysis 209 (32.6) 34 (34.3) 243 (32.8)
 Renal function tests 292 (45.5) 47 (47.5) 339 (45.8)
 Chest X-ray 114 (17.8) 18 (18.2) 132 (17.8)
 Echo 284 (44.2) 48 (48.5) 332 (44.8)
 ECG 290 (45.2) 51 (51.5) 341 (46.0)
Medication
 ACEi or ARB 464 (72.27) 75 (75.76) 539 (72.74)
 Beta blocker 345 (53.7) 42 (42.4) 387 (52.2)
 Calcium channel blocker 454 (70.7) 82 (82.8) 536 (72.3)
 Thiazide diuretic 438 (68.2) 70 (70.7) 508 (68.6)
 Centrally acting vasodilator 29 (4.5) 7 (7.1) 36 (4.9)
 Potassium sparing 21 (3.3) 3 (3.0) 24 (3.2)
 Furosemide 26 (4.1) 13 (13.1) 39 (5.3)
 Co-morbidity 23 (23.3) 67 (10.4) 90 (12.2)
 Blood pressure control 182 (28.4) 16 (16.2) 198 (26.7)
 Missed appointment 301 (47.9) 45 (46.4) 346 (47.7)
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BP  <  140/90  mmHg) at 26.7% which is inadequate in a 
country that has a high burden of hypertension [17, 18].
In this clinic, there were older people than the young, 
49.7% of patients were 60 years old and above with only 
5.7% below 40 years of age. This can be partly because in 
the young cause of hypertension is mainly renal disease 
(secondary hypertension) and these patients are reviewed 
in the renal clinic which independently runs on a differ-
ent clinic day [19].
Hypertension control was comparable across age 
groups but this is different from what has been revealed 
from community studies that found better control among 
patients less than 50  years [20]. Borzecki et  al. also 
found better blood pressure control among young adults 
but also noted that patients above 60  years were being 
treated less aggressively with fewer medications [21]. In 
our study, the number of drugs used across age groups 
wasn’t so varied.
Our finding illustrates a poor control compared to what 
Musinguzi et al. found in a community study, blood pres-
sure control among those on treatment was achieved by 
52 (35.9%) [17]. The possibility of white coat effect cannot 
be excluded, patients in the communities could be more 
relaxed compared to those in ambulatory clinics who 
might be anxious because of the long lines and long wait-
ing times. There is also the fact that this population was 
highly selected and those feeling bad (symptomatic) are 
more likely to attend the hypertension clinic.
Documentation of biophysical measurements and 
investigations was exceedingly poor in this hyperten-
sion clinic (Table 1). It is not easy from this to ascertain 
whether this low documentation is because these param-
eters were not done in the first place. Documentation 
enables the reviewing physician to make appropriate 
decisions for a patient such as choice of drugs, manage-
ment of side effects and co-morbidity, request additional 
tests as well as make appropriate referrals whenever 
needed. A simple measurement like weight can be crucial 
in monitoring patients with hypertension as this is cru-
cial in the control and prevention of complications.
Urinalysis to check for micro-albuminuria can easily be 
done to screen for renal disease and plan management. 
Our study reveals that only a third of the patients (32.8%) 
had a urinalysis done. According to a study done by Nab-
baale et al. in the same settings, 39.5% newly diagnosed 
hypertensive patients were found to have microalbumi-
nuria [22]. This implies that a sizable proportion of our 
hypertensive patients can be reviewed for years with 
undetected renal disease until the disease has progressed 
to a level which is expensive to manage. The low docu-
mentation for biophysical measurements and investiga-
tions clearly calls for protocol guided care in our clinic 
setting to guide patient management.
Majority of our patients were taking more than one 
drug for their blood pressure control, with 42.2% tak-
ing three drugs. Despite having several patients on more 
than one drug we still had poor BP control in this clinic 
setting. According to the Eighth Joint National Commit-
tee (JNC 8) [23], the recommended first line treatment 
for blacks with hypertension is a thiazide diuretic or cal-
cium channel blocker. ACEIs have been found to be less 
effective compared with the CCB in reducing BP in black 
individuals [24]. This is not necessarily the trend in our 
clinic, ACEI/ARBs are the most commonly prescribed 
drugs and whether this partly explains the lower rates of 
control needs further evaluation.
Black patients with hypertension and renal disease are 
recommended to take ACEI or ARBs according to the 
Table 2 Type of drugs used
ARBs angiotensin receptor blockers, ACEi angiotensin converting enzyme 
inhibitor
n (%)
One drug (5.8% n = 43)
 ARBs/ACEi 10 (23.3)
 Calcium channel blocker 10 (23.3)
 Diuretics 5 (11.6)
 Beta blocker 15 (34.9)
 Centrally acting vasodilator 1 (2.3)
 Potassium sparing diuretic 2 (4.6)
Two drugs (32.8% n = 243)
 ARBs/ACEi and beta blocker 33 (13.6)
 ARBs/ACEi and calcium channel blocker 66 (27.2)
 ARBs/ACEi and thiazide diuretic 37 (15.2)
 Beta blocker and calcium channel blocker 16 (6.6)
 Beta blocker and thiazide diuretic 37 (15.2)
 Others 6 (2.5)
Three drugs (42.2% n = 313)
 ARBs/ACEi, beta blocker and calcium channel blocker 53 (16.9)
 ARBs/ACEi, beta blocker and thiazide diuretic 42 (13.4)
 ARBs/ACEi calcium channel blocker and thiazide diuretic 149 (47.6)
 Beta blocker, calcium channel blocker and thiazide diuretic 55 (17.6)
 Others 14 (4.5)
Four drugs (16.5 n = 122)
 ARBs/ACEi, beta blocker, calcium channel blocker and 
thiazide diuretic
102 (83.6)
 ARBs/ACEi, calcium channel blocker thiazide diuretic and 
centrally acting vasodilator
6 (4.9)
 Others 14 (11.5)
Five drugs (1.9% n = 14)
 ARBs/ACEi, beta blocker, calcium channel blocker,  thiazide 
diuretic and centrally acting vasodilator
5 (35.7)
 ARBs/ACEi, beta blocker, calcium channel blocker, thiazide 
diuretic and potassium sparing diuretic
8 (57.1)
 ARBs/ACEi, beta blocker, calcium channel blocker, centrally 
acting vasodilator and potassium sparing diuretic
1 (7.1)
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African American Study of Kidney Disease and Hyper-
tension (AASK) [25]. Patients with CKD and hyperten-
sion usually require more than 1 drug to achieve goal BP 
and therefore an ACEI or ARB is used either as initial 
therapy or as second-line therapy in addition to a diu-
retic or CCB in black patients with CKD. However in our 
patient population little is known about CKD status and 
so use of ACEI or ARB is not from an informed point of 
view. This emphasizes the need to screen patients and 
also study this further in our patient population.
We found that majority of patients on monotherapy 
were taking beta blockers, this is not in line with the 
guidelines. Beta-blockers are not recommended for 
the initial treatment of hypertension because their use 
resulted in a higher rate of cardiovascular death, myocar-
dial infarction, or stroke [26]. Beta-blockers are readily 
available and cheap in Uganda, this could explain their 
common use.
This finding of low blood pressure control prompts us 
to consider other modalities that can contribute to bet-
ter blood pressure control. There have been studies that 
have shown that renal denervation may be a cost effective 
approach compared to medical management in manage-
ment of resistant hypertension [27, 28]. The use of renal 
denervation is still controversial with demonstrated no 
benefit from the Simplicity 3 trial [29], however some 
scholars believe that renal denervation done by expe-
rienced hands and good patient selection can be ben-
eficial. We cannot conclude though that all patients that 
had poor control have resistant hypertension but this is 
an aspect that needs consideration knowing that some 
patients could have resistant hypertension. In Africa, as 
we advance in catheter based interventions by our phy-
sicians; nerve denervation could be a welcome solution 
among patients with resistant hypertension.
This was a retrospective chart review study; we could 
not ascertain why control is low however we describe the 
magnitude of the problem and highlight key gaps in doc-
umentation. we cannot conclude that tests were not done 
since we went by what was documented but this clearly 
demonstrate that we have room to improve and make the 
care for our patients better.
Evaluation for a hypertensive patient ought to be com-
prehensive to identify risk factors, co-morbidity as well as 
stratify patients to risk categories and plan appropriate 
treatment. In a clinic setting there is opportunity to make 
management of hypertension better and consequently 
avert the bad outcomes that are associated with poor 
blood pressure control.
Conclusions
Blood pressure control is suboptimal in a clinic setting at 
Mulago hospital and documentation of basic investiga-
tions is inadequate. ARB/ACEI, Calcium channel block-
ers and thiazide diuretics were the commonly prescribed 
anti hypertensive medications. There is an urgent need 
to explore reasons for suboptimal control and institute 
Table 3 Factors associated with blood pressure control
ARBs angiotensin receptor blockers, ACEi angiotensin converting enzyme inhibitor
Variable Controlled blood pressure Uncontrolled blood pressure Odds ratio p value Adjusted odds ratio p value
Age 61 (51–71) 59 (50–70) 1.01 (1.00–1.02) 0.195
Gender—female 182 (91.9) 460 (84.7) 2.05 (1.17–3.60) 0.012 1.85 (1.03–3.34) 0.04
ARBs 78 (39.4) 232 (42.7) 0.87 (0.63–1.21) 0.416
ACEi 55 (27.8) 201 (37.0) 0.65 (0.46–0.93) 0.02 0.53 (0.36–0.78) 0.001
Beta blockers 94 (47.5) 293 (54.0) 0.77 (0.56–0.83) 0.118 0.62 (0.44–0.88) 0.008
Calcium channel blockers 127 (64.1) 409 (75.3) 0.58 (0.41–0.83) 0.003 0.54 (0.37–0.78) 0.002
Centrally acting 5 (2.53) 31 (5.71) 0.43 (0.16–1.12) 0.083 0.36 (0.13–0.98) 0.046
Thiazide diuretic 120 (60.6) 388 (71.5) 0.61 (0.44–0.86) 0.005 0.54 (0.38–0.78) 0.001
Potassium sparing 9 (4.55) 15 (2.76) 1.67 (0.72–3.89) 0.23
Number of anti-hypertensive drugs
 One 20 (10.1) 22 (4.1) [1]
 Two 82 (41.4) 154 (28.4) 0.59 (0.30–1.14) 0.113
 Three 69 (34.9) 239 (44.0) 0.32 (0.16–0.62) 0.001
 Four 18 (9.1) 116 (21.4) 0.17 (0.08–0.37) <0.001
 Five 5 (2.5) 9 (1.7) 0.61 (0.18–2.13) 0.44
 Having all investigations 24 (12.1) 79 (14.5) 0.81 (0.50–1.32) 0.399
 Having any comorbidity 25 (12.6) 65 (12.0) 1.06 (0.65–1.74) 0.809
 Keeping appointment 94 (48.2) 252 (47.5) 1.03 (0.74–1.43) 0.858
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measures to avert cardiovascular complications that are 
associated with poor blood pressure control.
Evaluation for a hypertensive patient ought to be com-
prehensive to identify risk factors, co-morbidity as well as 
stratify patients to risk categories and plan appropriate 
treatment. Protocols have to be put in place and imple-
mented for better patient care. In a clinic setting there is 
opportunity to make management of hypertension better 
and consequently avert the bad outcomes that are associ-
ated with poor blood pressure control.
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